Establishing the role of tigecycline in an era of antimicrobial resistance

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 5, 2008, Pages 557-567

  Schafer, Jason J ^a   Goff, Debra A ^b  

^a St Margaret Memorial Hospital   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Acinetobacter baumannii; Bacterial resistance; Extended spectrum lactamase; GAR 936; Glycylcyline; Tigecycline

Indexed keywords

AZTREONAM; CARBAPENEM; CILASTATIN PLUS IMIPENEM; DALFOPRISTIN PLUS QUINUPRISTIN; DIGOXIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METICILLIN; MINOCYCLINE; POLYMYXIN; POLYPEPTIDE ANTIBIOTIC AGENT; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN; WARFARIN;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONCENTRATION RESPONSE; CONSTIPATION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EUROPEAN UNION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HYPERTENSION; HYPOKALEMIA; INFECTION; INSOMNIA; LEUKOCYTOSIS; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NAUSEA AND VOMITING; NONHUMAN; PAIN; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL EDEMA; PHLEBITIS; PROTHROMBIN TIME; PRURITUS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; THROMBOCYTOPENIA; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; MINOCYCLINE; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME;

EID: 55249125730     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.5.557     Document Type: Article

References (58)

1. Meagher AK, Ambrose PG, Grasela TH, Eillis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis. 41, S333-S340 (2005).
2. Wyeth. Tygacil (tigecycline) package insert (2005).
3. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis. 41, S303-S314 (2005).
4. 2+ cleavage of 16S rRNA. J. Antimicrob. Chemother. 53, 592-599 (2004).
5. Bergeron J, Ammirati M, Danley D et al. Glycylcyclincs bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-Mediated ribosomal protection. Antimicrob. Agents Chemother. 40, 2226-2228 (1996).
6. Zhanel GG, Homenuik K, Nichol K. The glycylcyclines: a comparative review with the tetracyclines. Drugs 64, 63-88 (2004).
7. Van Wart SA, Cirincione BB, Ludwig EA et al. Population pharmacokinetics of tigecycline in healthy volunteers. J. Clin. Pharm. 47, 727-737 (2007).
8. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 49, 220-229 (2005).
9. Rodvold KA, Gotfried MH, Cwik M et al. Serum, rissue, and body fluid concentrations of tigecycline after a single 100mg dose. J. Antimicrob. Chemother. 58, 1221-1229 (2006).
10. van Ogtrop ML, Andes D, Stamstad TJ et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram positive and Gram negative bacteria. Antimicrob. Agents Chemother. 44, 943-949 (2000).
11. Conte JE, Golden JA, Kelly MG, Zurlinden E. Steady state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents 25, 523-529 (2005).
12. Sun HK, Ong CT, Umer A, Harper D, Troy S, Nightengale CH. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob. Agents Chemother. 49, 1629-1632 (2005).
13. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn. Microbiol. Infect. Dis. 52, 203-208 (2005).
14. Goff D, Dowzicky M. Prevalence and regional variation in methicillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial. J. Med. Microbiol. 56, 1189-1195 (2007).
15. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn. Microbiol. Infect. Dis. 52, 181-186 (2005).
16. Mendes RE, Sader HS, Deshpande L, Jones RN. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn. Microbiol. Infect. Dis. 60, 433-436 (2008).
17. Bouchillon S K, Hoban DJ, Johnson BM et al. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the USA Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn. Microbiol. Infect. Dis. 52, 173-179 (2005).
18. Fritsche TR, Sader SH, Stilwell MG et al. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. 52, 187-193 (2005).
19. Betriu C, Culebras E, Gomez M, Rodriguez-Avial I, Picazo JJ. In vitro activity of tigecycline against Bacteroides species. J. Antimicrob. Chemother. 56, 349-352 (2005).
20. Mendes RE, Fritsche TR, Sader HS, Jones RN. Increased antimicrobial susceptibility profiles among polymyxin-resistant Acinetobacter baumannii clinical isolates. Clin. Infect. Dis. 46, 1324-1326 (2008).
21. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob. Agents Chemother. 48, 4479-4481 (2004).
22. Conejo MC, Hernandez JR, Pascual A. Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended spectrum B-lactamases or plasmid-mediated AmpC-type B-lactamases. Diagn. Microbiol. Infect. Dis. (2008) (In Press).
23. Castahheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad spectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: report from the sentry antimicrobial surveillance program. Antimicrob Agents Chemother. 52, 570-573 (2008).
24. Peterson PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide- intermediate Staphylococcus aureus and other resistant Gram positive pathogens. Antimicrob. Agents Chemother. 46, 2595-2601 (2002).
25. Denys GA, Koch KM, Dowzicky MJ. Distribution of resistant Gram-positive organisms across the census regions of the USA and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Am. J. Infect. Control 35, 521-526 (2006).
26. Scheetz MH, Qi C, Warren JR et al In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51, 1621-1626 (2007).
27. Mezzatesta ML, Truvato G, Gona F et al. In vitro activity of tigecycline and comparators against carbapenem- susceptible and resistant Acinetobacter baumannii clinical isolates in Italy. Ann. Clin. Microbiol. Antimicrob. 7, 1-7 (2008).
28. Woodford N, Hill RLR, Livermore DM. In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp. J. Antimicrob. Chemother. 59, 582-583 (2007).
29. Insa R, Cercenado E, Goyanes MJ, Morente A, Bouza E. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 59, 583-584 (2007).
30. Hoban DJ, Bouchillon SK, Dowzicky MJ. Antimicrobial susceptibility of extended- spectrum β-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the USA and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diagn. Microbiol. Infect. Dis. 57, 423-428 (2007).
31. Curcio D, Fernandez F. Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective. J. Antimicrob. Chemother. 60, 449-450 (2007).
32. Laplante KL, Rybak MJ. Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn. Microbiol. Infect. Dis. 50, 125-130 (2004).
33. Souli M, Kontopidou F V, Koratzanis E et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals. Antimicrob. Agents Chemother. 50, 3166-3169 (2006).
34. Pliatsika V, Afkou Z, Protonotariou E, Sofianou D. In vitro activity of tigecycline against metallo-B-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother. 60, 1406-1407 (2007).
35. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PA01. Antimicrob. Agents Chemother. 47, 972-978 (2003).
36. Visalli MA, Murphy E, Projan SJ et al. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob. Agents Cbemother. 47, 665-669 (2003).
37. Peleg AY, Potoski BA, Rea R et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J. Antimicrob. Chemother. 59, 128-131 (2007).
38. Schafer JJ, Goff DA, Stevenson KB, Mangino JM. Early experience with tigecycline for the management of multi-drug resistant Acinetobacter baumannii ventilator associated pneumonia and/or bacteremia. Pharmacotherapy 27, 980-987 (2007).
39. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27, 1198-1201 (2007).
40. Peleg AY, Adams JA, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob. Agents Chemother. 51, 2065-2069 (2007).
41. Marchand I, Damier-Piolle L, Courvalin P, Lambert T. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob. Agents Chemother. 48, 3298-3304 (2004).
42. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob. Agents Chemother. 45, 3375-3380 (2001).
43. Muralidharan G, Fruncillo RJ, Micalizzi M et al. Effects of age and sex on single dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob. Agents Chemother. 49, 1656-1659 (2005).
44. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin structure infections in hospitalized patients. Clin. Ther. 26, 704-714 (2004).
45. Murray J, Wilson S, Klein S, Yellin A, Loh E. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a Phase 2 clinical trial. In: Program and Abstracts of the 43rd Conftrence of Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 14-17 September 2003. American Society of Microbiology, Abstract L-739, 416 (2003).
46. Babinchak T, Ellis-Grosse EJ, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of complicated intra-abdominal infections. Analysis of pooled clinical data. Clin. Infect. Dis. 41, S354-S367 (2005).
47. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41, S341-S353 (2005).
48. Tanaseanu C, Bergallo C, Teglia O et al. Integrated results of 2 Phase 3 studies comparing rigecycline and levofloxacin in community-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 61, 329-338 (2008).
49. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin. Infect. Dis. 46, 567-570 (2008).
50. Schafer JJ, Mangino JE. Multidrug- resistant Acinetobacter baumannii osteomyelitis from Iraq. Emerg. Infect. Dis. 14, 512-513 (2008).
51. Evagelopoulou. P, Myrianthefs P, Markogiannakis A, Baltopoulos G, Tsakris A. Multidrug-resistant Klebsiella pneumoniae mediastinitis safely and effectively treated with prolonged administration of tigecycline. Clin. Infect. Dis. 46, 1932-1933 (2008).
52. Wadi JA, Al Rub MA. Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline. Ann. Saudi Med. 27, 450-458 (2007).
53. Taccone FS, Rodriguez-Villalobos H, De Backer D et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur. J. Clin. Microbiol. Infect. Dis. 25, 257-260 (2006).
54. Khanna N, Inkster T. Methicillin-resistant Staphylococcus aureus hepatic abscess treated with tigecycline. J. Clin. Pathol. 61, 967-968 (2008).
55. Baines SD, Saxton K, Freeman J, Wilcox MH. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J. Antimicrob. Chemother. 58, 1062-1065 (2006).
56. Hecht DW, Galang MA, Sambol SP et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983-2004. Antimicrob. Agents Chemother. 51, 2716-2719 (2007).
57. Raible DG, Zimmerman JJ, Harper DM, Speth JL. Pharmacokinetics and pharmacodynamics of tigecycline and warfarin co-administered to healthy men. In: Program and Abstracts of the 44th Conftrence of Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30 October-2 November 2004.
58. Zimmerman JJ, Harper DM, Speth JL, Raible DG, Fruncillo, RJ. Tigecycline and digoxin co-administered to healthy men. In: Program and Abstracts of the 44th Conference of Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30 October-2 November 2004. (Abstract A-460).